Dipyridamole for Low Phosphate

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: Stanford University

No Placebo Group

Prior Safety Data

Trial Summary

What is the purpose of this trial?

The primary goal is to determine if Dipyridamole can improve serum phosphate levels and reduce the need for phosphate supplementation.

Research Team

Stephan Busque, MD

Principal Investigator

Stanford University

Eligibility Criteria

This trial is for kidney transplant recipients who may be at risk of developing low phosphate levels (hypophosphatemia) after their surgery. Specific eligibility criteria are not provided, but typically participants would need to meet certain health standards and not have conditions that could interfere with the study.

Inclusion Criteria

I have received a kidney transplant.

I am not allergic or sensitive to Dipyridamole.

Exclusion Criteria

I cannot take Dipyridamole due to health reasons.

I needed dialysis within a week after my transplant.

I need to take Plavix, DOACs, or Coumadin.

Treatment Details

Interventions

• Dipyridamole (Other)

Trial Overview The trial is testing whether Dipyridamole, given at a dose of 75 MG, can help maintain healthy phosphate levels in the blood and reduce the necessity for additional phosphate supplements post-kidney transplant.

Participant Groups

Group I: Treatment Group Experimental Treatment 1 Intervention

Participants receive Dipyridamole in addition to standard post-transplant care.

Group II: Control Group Active Control 1 Intervention

Participants in this group will receive standard post-transplant care without Dipyridamole.

Who Is Running the Clinical Trial?

Stanford University

Lead Sponsor

Trials

2,527

Recruited

17,430,000+